Omeros (NASDAQ:OMER) Downgraded by StockNews.com to Sell

StockNews.com cut shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a report published on Wednesday.

Other analysts have also issued research reports about the stock. D. Boral Capital reissued a “buy” rating and issued a $36.00 price target on shares of Omeros in a research report on Tuesday, April 1st. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Down 9.9 %

Omeros stock traded down $0.64 during trading on Wednesday, hitting $5.86. The stock had a trading volume of 483,794 shares, compared to its average volume of 565,428. The stock’s 50 day moving average is $8.31 and its two-hundred day moving average is $7.71. Omeros has a 1 year low of $2.97 and a 1 year high of $13.60. The stock has a market cap of $340.08 million, a price-to-earnings ratio of -2.52 and a beta of 2.35.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.08. During the same period in the prior year, the company posted ($0.15) EPS. As a group, equities research analysts anticipate that Omeros will post -3.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Omeros

Hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Omeros by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 1,110 shares during the period. Truvestments Capital LLC increased its stake in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,972 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of Omeros by 2.0% during the 4th quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company’s stock valued at $1,190,000 after acquiring an additional 2,317 shares during the last quarter. Finally, Cerity Partners LLC grew its holdings in shares of Omeros by 9.9% during the fourth quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 2,600 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.